Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (191-200 of 304) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced CancerLee S Rosen, Jonathan W Goldman, Alain P Algazi, et al.
JCI Insight|August 30, 2022
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosusEduardo Gomez-Bañuelos, M Javad Wahadat, Jessica Li, et al.
Environmental Science & Technology|October 20, 2022
Composition, Emissions, and Air Quality Impacts of Hazardous Air Pollutants in Unburned Natural Gas from Residential Stoves in CaliforniaEric D Lebel, Drew R Michanowicz, Kelsey R Bilsback, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Elife|May 24, 2022
The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular trapsBrendan Antiochos, Daniela Trejo-Zambrano, Paride Fenaroli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic TreatmentTimothy J Williamson, Alyssa K Choi, Julie C Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
BMC Cancer|March 28, 2013
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignanciesJonathan W Goldman, Robert N Raju, Gregory A Gordon, et al.
Radiology|December 13, 2017
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung CancerEmily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, et al.
Investigational New Drugs|July 18, 2016
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsLee S Rosen, Patricia LoRusso, Wen Wee Ma, et al.
Pageof 31

Showing results (191-200 of 304) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced CancerLee S Rosen, Jonathan W Goldman, Alain P Algazi, et al.
JCI Insight|August 30, 2022
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosusEduardo Gomez-Bañuelos, M Javad Wahadat, Jessica Li, et al.
Environmental Science & Technology|October 20, 2022
Composition, Emissions, and Air Quality Impacts of Hazardous Air Pollutants in Unburned Natural Gas from Residential Stoves in CaliforniaEric D Lebel, Drew R Michanowicz, Kelsey R Bilsback, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Elife|May 24, 2022
The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular trapsBrendan Antiochos, Daniela Trejo-Zambrano, Paride Fenaroli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic TreatmentTimothy J Williamson, Alyssa K Choi, Julie C Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
BMC Cancer|March 28, 2013
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignanciesJonathan W Goldman, Robert N Raju, Gregory A Gordon, et al.
Radiology|December 13, 2017
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung CancerEmily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, et al.
Investigational New Drugs|July 18, 2016
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsLee S Rosen, Patricia LoRusso, Wen Wee Ma, et al.
Pageof 31